Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up
Rocío Montes de(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Deepu Madduri(Johnson & Johnson (United States)), Brad Foulk(Janssen (United States)), Adam D. Cohen(Penn Center for AIDS Research), Sundar Jagannath(Mount Sinai Hospital), Cuc Davis(Janssen (United States)), Junchen Gu(Janssen (United States)), Yi Lin(Mayo Clinic), Denis A. Smirnov(Eon Corporation (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Kathy Zelinsky(Janssen (United States)), An‐Sofie Stevens(Janssen (Belgium)), Onsay Lau(Janssen (United States)), Jaymala Patel(Janssen (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), Dianna Wu(Memorial Sloan Kettering Cancer Center), Nahor Haddish‐Berhane, Sifan Xu, Rengasamy Boominathan(Janssen (United States)), Hao Zhao(Johnson & Johnson (United States)), Jieqing Zhu(490 BioTech (United States)), Jean Xu(Janssen (United States)), Dong Geng, Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 9
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k